Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
BMS trials update: CheckMate-67T posts results; two studies added for irAE care and lung screeningSep 25Weekly roundup, 5 itemsBristol Myers Squibbclarithromycin
Regeneron registers Phase 3 PICC clot-prevention trial; Sanofi runs sarilumab study as collaboratorJul 17Weekly roundup, 3 itemsamrecibartcenvacibart